These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 34028936)

  • 1. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer.
    Vernocchi P; Gili T; Conte F; Del Chierico F; Conta G; Miccheli A; Botticelli A; Paci P; Caldarelli G; Nuti M; Marchetti P; Putignani L
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33227982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers.
    Mao J; Wang D; Long J; Yang X; Lin J; Song Y; Xie F; Xun Z; Wang Y; Wang Y; Li Y; Sun H; Xue J; Song Y; Zuo B; Zhang J; Bian J; Zhang T; Yang X; Zhang L; Sang X; Zhao H
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34873013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis.
    Lu H; Gao NL; Tong F; Wang J; Li H; Zhang R; Ma H; Yang N; Zhang Y; Wang Y; Liang Z; Zeng H; Chen WH; Dong X
    Microbiol Spectr; 2021 Dec; 9(3):e0080221. PubMed ID: 34787462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
    Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
    Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
    Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
    J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review.
    Nagasaka M; Sexton R; Alhasan R; Rahman S; Azmi AS; Sukari A
    Crit Rev Oncol Hematol; 2020 Jan; 145():102841. PubMed ID: 31884204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody.
    Lee PJ; Hung CM; Yang AJ; Hou CY; Chou HW; Chang YC; Chu WC; Huang WY; Kuo WC; Yang CC; Lin KI; Hung KH; Chang LC; Lee KY; Kuo HP; Lu KM; Lai HC; Kuo ML; Chen WJ
    Gut Microbes; 2024; 16(1):2380061. PubMed ID: 39078050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
    Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
    Huang J; Liu D; Wang Y; Liu L; Li J; Yuan J; Jiang Z; Jiang Z; Hsiao WW; Liu H; Khan I; Xie Y; Wu J; Xie Y; Zhang Y; Fu Y; Liao J; Wang W; Lai H; Shi A; Cai J; Luo L; Li R; Yao X; Fan X; Wu Q; Liu Z; Yan P; Lu J; Yang M; Wang L; Cao Y; Wei H; Leung EL
    Gut; 2022 Apr; 71(4):734-745. PubMed ID: 34006584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
    Zhang F; Ferrero M; Dong N; D'Auria G; Reyes-Prieto M; Herreros-Pomares A; Calabuig-Fariñas S; Duréndez E; Aparisi F; Blasco A; García C; Camps C; Jantus-Lewintre E; Sirera R
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34063829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.
    Nucera F; Ruggeri P; Spagnolo CC; Santarpia M; Ieni A; Monaco F; Tuccari G; Pioggia G; Gangemi S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms.
    Yin H; Yang L; Peng G; Yang K; Mi Y; Hu X; Hao X; Jiao Y; Wang X; Wang Y
    Cancer Biol Med; 2021 May; 18(4):1040-52. PubMed ID: 33960176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
    Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.
    Zheng Y; Wang T; Tu X; Huang Y; Zhang H; Tan D; Jiang W; Cai S; Zhao P; Song R; Li P; Qin N; Fang W
    J Immunother Cancer; 2019 Jul; 7(1):193. PubMed ID: 31337439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising predictors of checkpoint inhibitor response in NSCLC.
    Alex F; Alfredo A
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):931-937. PubMed ID: 32870120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.